Evercore ISI Group Maintains Outperform on AbbVie, Raises Price Target to $260

Benzinga Newsdesk www.benzinga.com Positive 92.7%

Neg 0% Neu 0% Pos 92.7%

Evercore ISI Group analyst Gavin Clark-Gartner maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $246 to $260.